Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4747034
Max Phase: Preclinical
Molecular Formula: C51H65ClN10O12S
Molecular Weight: 1077.66
Molecule Type: Unknown
Associated Items:
ID: ALA4747034
Max Phase: Preclinical
Molecular Formula: C51H65ClN10O12S
Molecular Weight: 1077.66
Molecule Type: Unknown
Associated Items:
Canonical SMILES: Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCCCCCOCCOCCOCCOCCOCCOCC(=O)Nc3cccc4c3C(=O)N(C3CCC(=O)NC3=O)C4=O)CC2)n1
Standard InChI: InChI=1S/C51H65ClN10O12S/c1-34-9-7-11-37(52)46(34)59-48(66)40-32-53-51(75-40)57-41-31-42(55-35(2)54-41)61-18-16-60(17-19-61)15-5-3-4-6-20-69-21-22-70-23-24-71-25-26-72-27-28-73-29-30-74-33-44(64)56-38-12-8-10-36-45(38)50(68)62(49(36)67)39-13-14-43(63)58-47(39)65/h7-12,31-32,39H,3-6,13-30,33H2,1-2H3,(H,56,64)(H,59,66)(H,58,63,65)(H,53,54,55,57)
Standard InChI Key: FGTNRYWAENEKJL-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1077.66 | Molecular Weight (Monoisotopic): 1076.4193 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Kargbo RB.. (2020) Breakthrough in Degradation of BCR-ABL Fusion Protein for the Treatment of Cancer., 11 (12.0): [PMID:33335652] [10.1021/acsmedchemlett.0c00587] |
Source(1):